Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.66 | N/A | +2.78% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.66 | N/A | +2.78% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management conveyed a cautious outlook, emphasizing the need to navigate market challenges. They did not offer specific guidance for future performance.
Management expressed uncertainty about future revenue growth.
They highlighted ongoing challenges in the market.
No specific guidance was provided for upcoming quarters.
AbbVie's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. However, the stock fell by 3.84%, likely due to management's cautious tone and lack of forward guidance. Investors may be concerned about the company's ability to sustain growth in a challenging market environment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UNIVERSAL HEALTH SVC Class B
Oct 25, 2022